global pricing gap Ryzneuta® Highlights the 14× China–U.S. Drug Pricing Gap Ryzneuta® (efbemalenograstim alfa) highlights a 13–14× U.S.–China pricing gap, illustrating the challenges and opportunities for Chinese biologics in global markets.